- Home
- NVCR vs XERS Comparison
NVCR vs XERS Comparison
Compare NVCR & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- XERS
- Stock Information
- Founded
- NVCR 2000
- XERS 2005
- Country
- NVCR Switzerland
- XERS United States
- Employees
- NVCR N/A
- XERS N/A
- Industry
- NVCR Medical/Dental Instruments
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- NVCR Health Care
- XERS Health Care
- Exchange
- NVCR Nasdaq
- XERS Nasdaq
- Market Cap
- NVCR 1.4B
- XERS 1.3B
- IPO Year
- NVCR 2015
- XERS 2018
- Fundamental
- Price
- NVCR $13.77
- XERS $9.20
- Analyst Decision
- NVCR Buy
- XERS Strong Buy
- Analyst Count
- NVCR 7
- XERS 7
- Target Price
- NVCR $28.79
- XERS $8.00
- AVG Volume (30 Days)
- NVCR 1.6M
- XERS 2.2M
- Earning Date
- NVCR 10-30-2025
- XERS 11-06-2025
- Dividend Yield
- NVCR N/A
- XERS N/A
- EPS Growth
- NVCR N/A
- XERS N/A
- EPS
- NVCR N/A
- XERS N/A
- Revenue
- NVCR $630,160,000.00
- XERS $246,025,000.00
- Revenue This Year
- NVCR $6.68
- XERS $43.89
- Revenue Next Year
- NVCR $7.01
- XERS $20.40
- P/E Ratio
- NVCR N/A
- XERS N/A
- Revenue Growth
- NVCR 14.58
- XERS 35.62
- 52 Week Low
- NVCR $10.87
- XERS $2.82
- 52 Week High
- NVCR $34.13
- XERS $9.49
- Technical
- Relative Strength Index (RSI)
- NVCR 51.39
- XERS 65.97
- Support Level
- NVCR $13.57
- XERS $8.99
- Resistance Level
- NVCR $14.58
- XERS $9.41
- Average True Range (ATR)
- NVCR 0.64
- XERS 0.41
- MACD
- NVCR -0.05
- XERS 0.05
- Stochastic Oscillator
- NVCR 49.59
- XERS 85.96
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).